A secondary heart attack could be prevented by replacing 30 minutes of sedentary behavior with light-intensity or moderate-to ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

The SELECT trial, first conducted in 2023, demonstrated that semaglutide could reduce the risk of major heart events—such as ...

Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Eli Lilly has announced that its Zepbound (tirzepatide) was superior to Novo Nordisk’s Wegovy (semaglutide) across all weight ...

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

Denmark’s Novo Nordisk has presented data at the European Congress of Obesity (ECO) showing that Wegovy (semaglutide ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...